Subjective THC Tolerance Did Not Eliminate Cardiovascular Responses

Feeling less intoxicated after repeated THC dosing does not establish that every physiological response has diminished. A short residential study in daily cannabis smokers reported tolerance to subjective intoxication while cardiovascular effects persisted.

A closely supervised oral regimen

The study involved thirteen healthy male daily cannabis smokers on a secure research unit. Participants received repeated oral synthetic THC over six days, with scheduled doses totaling up to 120 milligrams per day near the end. This unusually intensive research regimen is not a dosing recommendation.

Different outcomes followed different patterns

Morning intoxication ratings rose early and then declined on later study days. The morning dose also produced less additional subjective intoxication later in the regimen, a pattern consistent with tolerance. Blood pressure and heart-rate effects did not show the same tolerance pattern.

The measurements were plasma concentrations

Plasma THC and 11-hydroxy-THC increased over the first five dosing days. Declining subjective ratings therefore did not mean that exposure was falling. Plasma is the liquid fraction separated from blood; these findings should not be recast as whole-blood thresholds.

The distinction is practical: subjective adaptation, cardiovascular responses and drug accumulation are separate outcomes. None substitutes for an actual driving or cognitive assessment. The sample was small, male and already experienced with daily cannabis use, and the observation period was short. The result supports an effect-specific description of tolerance rather than a claim that repeated use makes a person globally unaffected by THC.

Related: interpreting cannabis tolerance claims.

Research cited

Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA. Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. Journal of analytical toxicology (2013). doi:10.1093/jat/bks081. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

A rodent study found pain-related benefits from activating an endogenous adenosine pathway independently of opioid and endocannabinoid mechanisms. Endogenous pain modulation is therefore not automatically evidence of cannabinoid-receptor involvement. The intervention targeted adenosine signaling Researchers increased endogenous adenosine through kinase inhibition and separately tested a selective A3-receptor agonist. Receptor blockade…

Spread the love

Read Article: An Endogenous Pain Pathway Worked Independently of Endocannabinoid Mechanisms in Rodents

Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Danish methadone-fatality study reported extensive mixed-drug exposure, including cannabis, and used segmental hair analysis to extend the exposure history beyond blood testing. That additional history was not proof of simultaneous intoxication from every listed substance. The two matrices supplied different information The study examined fatalities with both blood and…

Spread the love

Read Article: Cannabis in a Mixed-Drug Fatality Series: Hair and Blood Answer Different Exposure Questions

A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

A 2015 review included cannabinoids among options for refractory cancer pain while describing weak benefit evidence across the reviewed drug strategies. Inclusion on a treatment-options list did not establish superiority or a favorable outcome for every patient. Refractory pain was a specific clinical question The review concerned pain not adequately…

Spread the love

Read Article: A Refractory Cancer-Pain Review’s Cannabinoid Option Was Not an Evidence-Based Ranking of Add-On Treatments

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us